The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Randomized Phase II Trial of Concurrent Cisplatin-Radiotherapy With or Without Neoadjuvant Docetaxel and Cisplatin in Advanced Nasopharyngeal Carcinoma
Open accessAbstract
Purpose: To compare the toxicities, tumor control, survival, and quality of life of nasopharyngeal cancer (NPC) patients treated with sequential neoadjuvant chemotherapy followed by concurrent cisplatin-radiotherapy (CRT) or CRT alone. Patients and Methods: Previously untreated stage III to IVB NPC were randomly assigned to (1) neoadjuvant docetaxel 75 mg/m 2 and cisplatin 75 mg/m 2 every 3 weeks for two cycles, followed by cisplatin 40 mg/m 2 /wk concurrent with radiotherapy, or (2) CRT alone. Planned accrual was 30 patients per arm to detect 20% difference of toxicities based on 95% CIs. Results: From November 2002 to November 2004, 65 eligible patients were randomly assigned to neoadjuvant chemotherapy followed by CRT (n = 34) or CRT alone (n = 31). There was a high rate of grade 3/4 neutropenia (97%) but not neutropenic fever (12%) during neoadjuvant chemotherapy. No significant differences in rates of acute toxicities were observed between the two arms during CRT. Dose intensities of concurrent cisplatin, late RT toxicities and quality of life scores were comparable in both arms. The 3-year progression-free survival for neoadjuvant versus control arm was 88.2% and 59.5% (hazard ratio = 0.49; 95% CI, 0.20 to 1.19; P = .12). The 3-year overall survival for neoadjuvant versus control arm was 94.1% and 67.7% (hazard ratio = 0.24; 95% CI, 0.078 to 0.73; P = .012). Conclusion: Neoadjuvant docetaxel-cisplatin followed by CRT was well tolerated with a manageable toxicity profile that allowed subsequent delivery of full-dose CRT. Preliminary results suggested a positive impact on survival. A phase III study to definitively test this neoadjuvant-concurrent strategy is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Cox, J. D., Stetz, J., & Pajak, T. F. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)00060-c · Cited by 4,792
Morris, M., Eifel, P. J., Lu, J., Grigsby, P. W., Levenback, C., Stevens, R. E., Rotman, M., Gershenson, D. M., & Mutch, D. G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904153401501 · Cited by 2,299
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
Vermorken, J. B., Remenar, E., van Herpen, C., Gorlia, T., Mesia, R., Degardin, M., Stewart, J. S., Jelic, S., Betka, J., Preiss, J. H., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071028 · Cited by 1,719
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
Posner, M. R., Hershock, D. M., Blajman, C. R., Mickiewicz, E., Winquist, E., Gorbounova, V., Tjulandin, S., Shin, D. M., Cullen, K., Ervin, T. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070956 · Cited by 1,705
Bjordal, K., Hammerlid, E., Ahlner-Elmqvist, M., de Graeff, A., Boysen, M., Evensen, J. F., Biörklund, A., de Leeuw, J. R. J., Fayers, P. M., Jannert, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.1008 · Cited by 862
Chan, A. T. C., Teo, P. M. L., Ngan, R. K., Leung, T. W., Lau, W. H., Zee, B., Leung, S. F., Cheung, F. Y., Yeo, W., Yiu, H. H., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.149 · Cited by 474
Self-citation(1996) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)80007-1 · Cited by 338
Chua, D. T. T., Ma, J., Sham, J. S. T., Mai, H.-Q., Choy, D. T. K., Hong, M.-H., Lu, T.-X., & Min, H.-Q. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.081 · Cited by 242
Chan, A. T. �., Ma, B. B. Y., Lo, Y. M. D., Leung, S. F., Kwan, W. H., Hui, E. P., Mok, T. S. K., Kam, M. K. M., Chan, L. S., Chiu, S. K. W., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.178 · Cited by 132
Self-citationLiu, F., Chang, J. T., Wang, H., Liao, C., Kang, C., Ng, S.-K., Chan, S.-C., & Yen, T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8760 · Cited by 98
Neoadjuvant Cisplatin Chemotherapy Before Chemoradiation: A Flawed Paradigm?
Glynne‐Jones, R., & Hoskin, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3133 · Cited by 63
Au, E., Tan, E. H., & Ang, P. T. (1998) · Annals of Oncology · doi:10.1023/a:1008255220284 · Cited by 59
Approach to a multiparametric sensor-chip-based tumor chemosensitivity assay
Henning, T. D., Brischwein, M., Baumann, W., et al. (2001) · Anti-Cancer Drugs · doi:10.1097/00001813-200101000-00004 · Cited by 49
Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma
Ma, B. B. Y., & Chan, A. T. �. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.3.383 · Cited by 41
Self-citation
Cited by
Chen, Y.-P., Chan, A. T. C., Le, Q.-T., Blanchard, P., Sun, Y., & Ma, J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30956-0 · Cited by 3,077
Self-citationChua, M. L. K., Wee, J. T. S., Hui, E. P., & Chan, A. T. C. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00055-0 · Cited by 1,236
Self-citationSun, Y., Li, W.-F., Chen, N.-Y., Zhang, N., Hu, G.-Q., Xie, F.-Y., Sun, Y., Chen, X.-Z., Li, J.-G., Zhu, X.-D., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30410-7 · Cited by 950
Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective
Lee, A. W. M., Ma, B. B. Y., Ng, W. T., & Chan, A. T. C. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.9347 · Cited by 796
Self-citationChemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis
Blanchard, P., Lee, A., Marguet, S., Leclercq, J., Ng, W. T., Ma, J., Chan, A. T. C., Huang, P.-Y., Benhamou, E., Zhu, G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70126-9 · Cited by 755
Self-citation
Metadata
- Authors
- Hui, E. P., Ma, B. B., Leung, S. F., King, A. D., Mo, F., Kam, M. K., Yu, B. K., Chiu, S. K., Kwan, W. H., Ho, R., Chan, I., Ahuja, A. T., Zee, B. C., & Chan, A. T.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-01-10
- Volume
- 27
- Issue
- 2
- Pages
- 242-249
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2160982012
- Cited by
- 523
- References
- 16
- FWCI
- 13.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.